Benefit-risk paradigm for clinical trial design of obesity devices: FDA proposal
- 18 December 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Surgical Endoscopy
- Vol. 27 (3), 702-707
- https://doi.org/10.1007/s00464-012-2724-3
Abstract
Diet and exercise, except in controlled circumstances, have not been shown to provide effective and prolonged weight loss for the majority of those who are obese. Several older drugs intended to reduce weight have been withdrawn from the market, and the new drugs show only modest weight loss. Surgical intervention, specifically procedures that alter the normal gastrointestinal anatomy, does provide prolonged periods of sustained weight loss, with rebound weight gain over time. A variety of medical devices to assist in weight reduction have been studied, but only two are legally marketed devices for obesity. The authors propose a new paradigm for devices intended to treat obesity, based on a benefit-risk determination, with the hope to provide sponsors an a priori tool for systematic assessment of the risks associated with the devices intended for treatment of obesity and to suggest appropriate levels of benefit for devices with different risk levels. The paradigm is not intended to determine the class of a device from a regulatory perspective. This approach was conceived at a Food and Drug Administration (FDA) co-sponsored workshop in October, 2011 and formally presented to an FDA advisory panel for discussion in May 2012.Keywords
This publication has 14 references indexed in Scilit:
- Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 DiabetesDiabetes Care, 2011
- The effectiveness of adjustable gastric banding: a retrospective 6-year U.S. follow-up studySurgical Endoscopy, 2010
- The Impact of Bariatric Surgery on Comorbidities and Medication Use Among Obese PatientsObesity Surgery, 2010
- The incidence of co-morbidities related to obesity and overweight: A systematic review and meta-analysisBMC Public Health, 2009
- Association of Hypertension, Diabetes, Dyslipidemia, and Metabolic Syndrome with Obesity: Findings from the National Health and Nutrition Examination Survey, 1999 to 2004Journal of the American College of Surgeons, 2008
- Association of Overweight With Increased Risk of Coronary Heart Disease Partly Independent of Blood Pressure and Cholesterol LevelsA Meta-analysis of 21 Cohort Studies Including More Than 300 000 PersonsArchives of Internal Medicine, 2007
- Weight Loss in Overweight Adults and the Long-term Risk of HypertensionArchives of Internal Medicine, 2005
- Prevention of Type 2 Diabetes Mellitus by Changes in Lifestyle among Subjects with Impaired Glucose ToleranceThe New England Journal of Medicine, 2001
- Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health.1998
- American Heart Association Call to Action: Obesity as a Major Risk Factor for Coronary Heart DiseaseCirculation, 1998